Wedbush Securities said that among the companies it covered in Life Sciences this week Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) are reporting earnings.
The research department of Wedbush said Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) will be presenting linaclotide results from Phase 3 clinical trials in patients with irritable bowel syndrome with constipation (IBS?C) during the 2011 Digestive Disease Week (DDW) annual meeting that will be held in Chicago from May 7 through May 10, 2011. In addition, Ironwood will host its first quarter 2011 investor update conference call on May 12.
Wedbush said BioMimetic Therapeutics Inc. (NASDAQ: BMTI) will participate in a Food and Drug Administration (FDA) Orthopedic and Rehabilitation Devices Panel meeting on May 12 to review the company’s Premarket Approval (PMA) application for Augment Bone Graft for the treatment of foot and ankle fusions in the U.S.
The research department of Wedbush said Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) will hold its Annual R&D Day on May 12 in New York. Members of Lexicon's senior management team will provide in-depth reviews of the company's clinical programs and an overview of several other preclinical programs in the company's pipeline.
The review of Lexicon's clinical programs will include a presentation of results obtained to date from carcinoid syndrome patients participating in the European Union-based open-label clinical trial of LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.
The event calendar is as follows: